Skip to Content
Merck
  • Simultaneous determination of the UV-filters benzyl salicylate, phenyl salicylate, octyl salicylate, homosalate, 3-(4-methylbenzylidene) camphor and 3-benzylidene camphor in human placental tissue by LC-MS/MS. Assessment of their in vitro endocrine activity.

Simultaneous determination of the UV-filters benzyl salicylate, phenyl salicylate, octyl salicylate, homosalate, 3-(4-methylbenzylidene) camphor and 3-benzylidene camphor in human placental tissue by LC-MS/MS. Assessment of their in vitro endocrine activity.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (2013-09-06)
I Jiménez-Díaz, J M Molina-Molina, A Zafra-Gómez, O Ballesteros, A Navalón, M Real, J M Sáenz, M F Fernández, N Olea
ABSTRACT

UV-filters are widely used in many personal care products and cosmetics. Recent studies indicate that some organic UV-filters can accumulate in biota and act as endocrine disruptors, but there are few studies on the occurrence and fate of these compounds in humans. In the present work, a new liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to assess the presence of six UV-filters in current use (benzyl salicylate, phenyl salicylate, octyl salicylate, homosalate, 3-(4-methylbenzylidene) camphor, and 3-benzylidene camphor) in human placental tissue is proposed. The method involves the extraction of the analytes from the samples using ethyl acetate, followed by a clean-up step using centrifugation prior to their quantification by LC-MS/MS using an atmospheric pressure chemical ionization (APCI) interface. Bisphenol A-d16 was used as surrogate for the determination of benzyl salicylate, phenyl salicylate, octyl salicylate and homosalate in negative mode and benzophenone-d10, was used as surrogate for the determination of 3-(4-methylbenzylidene) camphor and 3-benzylidene camphor in positive mode. The found limits of detection ranged from 0.4 to 0.6ngg(-1) and the limits of quantification ranged from 1.3 to 2.0ngg(-1), while variability was under 13.7%. Recovery rates for spiked samples ranged from 97% to 104%. Moreover, the interactions of these compounds with the human estrogen receptor alpha (hERα) and androgen receptor (hAR), using two in vitro bioassays based on reporter gene expression and cell proliferation assessment, were also investigated. All tested compounds, except benzyl salicylate and octyl salicylate, showed estrogenic activity in the E-Screen bioassay whereas only homosalate and 3-(4-methylbenzylidene) camphor were potent hAR antagonists. Although free salicylate derivatives and free camphor derivatives were not detected in the human placenta samples analyzed, the observed estrogenic and anti-androgenic activities of some of these compounds support the analysis of their occurrence and their role as endocrine disrupters in humans.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
(±)-Camphor, ≥95.5%
Sigma-Aldrich
(±)-Camphor, purum, synthetic, ≥95.0% (GC)
Sigma-Aldrich
(±)-Camphor, meets analytical specification of Ph. Eur., BP, racemic, ≥95% (GC)
Sigma-Aldrich
Camphor, 96%
Sigma-Aldrich
(1R)-(+)-Camphor, 98%
Supelco
(−)-Camphor, analytical standard
Camphor (racemic), European Pharmacopoeia (EP) Reference Standard
Camphor (dl), primary reference standard
Sigma-Aldrich
(1S)-(−)-Camphor, 95%
Sigma-Aldrich
D-Camphor, ≥97%, FG
Supelco
D-Camphor, Pharmaceutical Secondary Standard; Certified Reference Material